These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 6143743

  • 1. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
    Johnson DA.
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
    [Abstract] [Full Text] [Related]

  • 2. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA.
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [Abstract] [Full Text] [Related]

  • 3. Depot neuroleptics: side effects and safety.
    Marder SR.
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):24S-29S. PubMed ID: 2870089
    [Abstract] [Full Text] [Related]

  • 4. Depot neuroleptic therapy: an underutilized treatment option.
    Glazer WM, Kane JM.
    J Clin Psychiatry; 1992 Dec; 53(12):426-33. PubMed ID: 1362569
    [Abstract] [Full Text] [Related]

  • 5. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ.
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [Abstract] [Full Text] [Related]

  • 6. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS, Stewart DW.
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [Abstract] [Full Text] [Related]

  • 7. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics.
    Möller HJ, Kissling W.
    Clin Neuropharmacol; 1986 Nov; 9 Suppl 4():259-62. PubMed ID: 2882841
    [No Abstract] [Full Text] [Related]

  • 8. Relapse and rehospitalization: comparing oral and depot antipsychotics.
    Schooler NR.
    J Clin Psychiatry; 2003 Nov; 64 Suppl 16():14-7. PubMed ID: 14680414
    [Abstract] [Full Text] [Related]

  • 9. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
    Bhanji NH, Chouinard G, Margolese HC.
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
    [Abstract] [Full Text] [Related]

  • 10. Depot fluphenazine: risk/benefit ratio.
    Glazer WM.
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):28-35. PubMed ID: 6370986
    [Abstract] [Full Text] [Related]

  • 11. Clinical review of a long-acting, injectable formulation of risperidone.
    Knox ED, Stimmel GL.
    Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
    [Abstract] [Full Text] [Related]

  • 12. Noncompliance with antiparkinsonian medications in neuroleptic-treated schizophrenic patients: three cases of an unreported phenomenon.
    Bermanzohn PC, Siris SG.
    J Clin Psychiatry; 1994 Nov; 55(11):488-91. PubMed ID: 7989282
    [Abstract] [Full Text] [Related]

  • 13. The case for long-acting antipsychotic agents in the post-CATIE era.
    Nasrallah HA.
    Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
    [Abstract] [Full Text] [Related]

  • 14. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM.
    J Clin Psychiatry; 2006 Apr; 67 Suppl 5():9-14. PubMed ID: 16822091
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Approaches to the problem of preventing hazards of long-term neuroleptic treatment and of avoiding unnecessary drugs.
    Kristjansen P.
    Adv Biochem Psychopharmacol; 1980 Apr; 24():505-11. PubMed ID: 6105796
    [No Abstract] [Full Text] [Related]

  • 18. Depot neuroleptic therapy: clinical considerations.
    Remington GJ, Adams ME.
    Can J Psychiatry; 1995 Apr; 40(3 Suppl 1):S5-11. PubMed ID: 7627927
    [Abstract] [Full Text] [Related]

  • 19. Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism.
    Babiker IE.
    J Clin Psychiatry; 1987 Mar; 48(3):94-7. PubMed ID: 2880839
    [Abstract] [Full Text] [Related]

  • 20. Long-term depot antipsychotics. A risk-benefit assessment.
    Barnes TR, Curson DA.
    Drug Saf; 1994 Jun; 10(6):464-79. PubMed ID: 7917075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.